"#FDA grants IDE approval to use #OncologyVenture’s #LiPlaCis DRP for patient selection in a pivotal Phase 3 study $OV https://t.co/lNqnwBu4yL"

LiPlaCis (liposomal cisplatin) - Oncology Venture

Aug 18, 2019